- To evaluate the efficacy of the different treatment combinations in patients with limited, locally advanced or metastatic solid tumors by assessing objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and immune-related RECIST (irRECIST).